Literature DB >> 17245761

Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease.

Susanna Levy1, Matthew McConville, Glorie A Lazaro, Paul Averback.   

Abstract

A specific and reliable competitive affinity assay kit has been developed to quantitatively measure neural thread protein (NTP) in first morning urine samples. This assay, called the urine neural thread protein test (UNTP), is a competitive enzyme-linked immunosorbent assay (ELISA) format affinity assay using 32-well microtiter plates. The assay detects UNTP in the 10-60 microg/mL range (an improvement over earlier assays of 10(3) x ), is linear and more reproducible (average coefficient of variation [CV] 6.2% in precision studies). The utility of the assay has been demonstrated in urine samples from patients with Alzheimer's disease (AD) and controls (sensitivity of 90% and specificity of 91%). Test-retest assays of subjects with AD and controls were comparatively stable at intervals of 2 days to 4.5 years, which suggests that positive (elevated) or negative (normal) NTP levels do not fluctuate significantly over time with respect to the cutoff. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245761      PMCID: PMC6649306          DOI: 10.1002/jcla.20159

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  30 in total

Review 1.  Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

Review 2.  Biochemical diagnostic markers to detect early Alzheimer's disease.

Authors:  L Lannfelt
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

3.  Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid.

Authors:  S M Monte; K Ghanbari; W H Frey; I Beheshti; P Averback; S L Hauser; H A Ghanbari; J R Wands
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

4.  Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls.

Authors:  T Pirttilä; K S Kim; P D Mehta; H Frey; H M Wisniewski
Journal:  J Neurol Sci       Date:  1994-12-01       Impact factor: 3.181

5.  Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype.

Authors:  R M Nitsch; G W Rebeck; M Deng; U I Richardson; M Tennis; D B Schenk; C Vigo-Pelfrey; I Lieberburg; R J Wurtman; B T Hyman
Journal:  Ann Neurol       Date:  1995-04       Impact factor: 10.422

6.  Documentation and evaluation of cognitive impairment in elderly primary care patients.

Authors:  C M Callahan; H C Hendrie; W M Tierney
Journal:  Ann Intern Med       Date:  1995-03-15       Impact factor: 25.391

7.  Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.

Authors:  W A Munroe; P C Southwick; L Chang; D W Scharre; C L Echols; P C Fu; J M Whaley; R L Wolfert
Journal:  Ann Clin Lab Sci       Date:  1995 May-Jun       Impact factor: 1.256

8.  Epidemiology of clinically diagnosed Alzheimer's disease.

Authors:  W A Rocca; L A Amaducci; B S Schoenberg
Journal:  Ann Neurol       Date:  1986-05       Impact factor: 10.422

9.  Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain.

Authors:  T Pirttilä; P D Mehta; H Soininen; K S Kim; O Heinonen; L Paljärvi; O Kosunen; P Riekkinen; H M Wisniewski
Journal:  Arch Neurol       Date:  1996-02

10.  Validity of clinical diagnosis in dementia: a prospective clinicopathological study.

Authors:  P K Mölsä; L Paljärvi; J O Rinne; U K Rinne; E Säkö
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-11       Impact factor: 10.154

View more
  6 in total

1.  CSF Biomarkers for Alzheimer's Disease Diagnosis.

Authors:  A Anoop; Pradeep K Singh; Reeba S Jacob; Samir K Maji
Journal:  Int J Alzheimers Dis       Date:  2010-06-23

Review 2.  Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease.

Authors:  Christopher D Aluise; Renã A Sowell; D Allan Butterfield
Journal:  Biochim Biophys Acta       Date:  2008-08-07

Review 3.  Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

4.  Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.

Authors:  Nan Zhang; Liling Zhang; Yan Li; Marc L Gordon; Li Cai; Ying Wang; Mengya Xing; Yan Cheng
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 5.  Advances in the development paradigm of biosample-based biosensors for early ultrasensitive detection of alzheimer's disease.

Authors:  Hem Prakash Karki; Yeongseok Jang; Jinmu Jung; Jonghyun Oh
Journal:  J Nanobiotechnology       Date:  2021-03-09       Impact factor: 10.435

Review 6.  The China Alzheimer Report 2022.

Authors:  Rujing Ren; Jinlei Qi; Shaohui Lin; Xinya Liu; Peng Yin; Zhihui Wang; Ran Tang; Jintao Wang; Qiang Huang; Jianping Li; Xinyi Xie; Yongbo Hu; Shishuang Cui; Yuan Zhu; Xiaoping Yu; Pengfei Wang; Yikang Zhu; Yiran Wang; Yanyan Huang; Yisong Hu; Ying Wang; Chunbo Li; Maigeng Zhou; Gang Wang
Journal:  Gen Psychiatr       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.